Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy A multicentre study of the French Fédération Nationale des Centres de Lutte Contre le Cancer

摘要: Summary Background Because of its antitumour activity and pharmacological advantage when administered by the intraperitoneal route, carboplatin was studied in a phase II multicen-tric trial. The aim study to determine response rate toxicity intraperito-neally if pathological complete could be attained women with macroscopic residual ovarian cancer at second-look laparotomy after intravenous cis-platin chemotherapy. Patients methods Twenty-nine patients macroscopical disease cisplatin-based chemotherapy laparotomy, were treated that time 300 mg/m2 abdominal cavity every four weeks for six cycles. In instances negative findings physical CT scan examination, evaluation performed catheter removed. dose increased or decreased according hematological toxicity. Results Efficacy is evaluable 25 pts: 2 pts had responses 1 pt microscopic (12% patients). Toxicity 135 cycles 29 patients. No grade 4 observed, 3 leukopenia thrombocytopenia; vomiting observed 11% peritoneal complication observed; dysfunction occurred first cycle one patient who refused surgical procedure remove pursue treatment. Conclusions Intraperitoneal demonstrates efficacy first-line cisplatin recommended further studies weeks. A low does not favour randomised study.